JP6277187B2 - ヒト胚性幹細胞由来の間葉系様幹細胞、方法およびその使用 - Google Patents

ヒト胚性幹細胞由来の間葉系様幹細胞、方法およびその使用 Download PDF

Info

Publication number
JP6277187B2
JP6277187B2 JP2015521809A JP2015521809A JP6277187B2 JP 6277187 B2 JP6277187 B2 JP 6277187B2 JP 2015521809 A JP2015521809 A JP 2015521809A JP 2015521809 A JP2015521809 A JP 2015521809A JP 6277187 B2 JP6277187 B2 JP 6277187B2
Authority
JP
Japan
Prior art keywords
msc
cells
mscs
cell
stem cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015521809A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015523083A5 (OSRAM
JP2015523083A (ja
Inventor
ワン，シアオファン
ス，レン−ヘ
Original Assignee
イムステム バイオテクノロジー，インコーポレイテッド
イムステム バイオテクノロジー，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イムステム バイオテクノロジー，インコーポレイテッド, イムステム バイオテクノロジー，インコーポレイテッド filed Critical イムステム バイオテクノロジー，インコーポレイテッド
Publication of JP2015523083A publication Critical patent/JP2015523083A/ja
Publication of JP2015523083A5 publication Critical patent/JP2015523083A5/ja
Application granted granted Critical
Publication of JP6277187B2 publication Critical patent/JP6277187B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/135—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2529/00—Culture process characterised by the use of electromagnetic stimulation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2015521809A 2012-07-11 2013-07-11 ヒト胚性幹細胞由来の間葉系様幹細胞、方法およびその使用 Active JP6277187B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261670192P 2012-07-11 2012-07-11
US61/670,192 2012-07-11
US201261684509P 2012-08-17 2012-08-17
US61/684,509 2012-08-17
PCT/US2013/050077 WO2014011881A2 (en) 2012-07-11 2013-07-11 Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof

Publications (3)

Publication Number Publication Date
JP2015523083A JP2015523083A (ja) 2015-08-13
JP2015523083A5 JP2015523083A5 (OSRAM) 2016-09-01
JP6277187B2 true JP6277187B2 (ja) 2018-02-07

Family

ID=49916687

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015521809A Active JP6277187B2 (ja) 2012-07-11 2013-07-11 ヒト胚性幹細胞由来の間葉系様幹細胞、方法およびその使用

Country Status (7)

Country Link
US (4) US9725698B2 (OSRAM)
EP (1) EP2872619B1 (OSRAM)
JP (1) JP6277187B2 (OSRAM)
CN (1) CN104487568B (OSRAM)
AU (1) AU2013290146B2 (OSRAM)
CA (2) CA2876512C (OSRAM)
WO (1) WO2014011881A2 (OSRAM)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2013331A2 (en) 2006-04-14 2009-01-14 Advanced Cell Technology, Inc. Hemangio-colony forming cells
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
US20160095885A1 (en) * 2014-10-01 2016-04-07 WibiWorks Therapeutics, Inc. Induction Medium & Methods for Stem Cell Culture & Therapy
US20180355319A1 (en) * 2015-08-07 2018-12-13 Kyoto Prefectural Public University Corporation Method for preparing brown adipocyte
KR101779932B1 (ko) * 2015-09-15 2017-09-21 주식회사 스템랩 나노그(Nanog)를 도입한 양수 내 태아 유래 중간엽 줄기세포를 이용한 육모 촉진용 조성물의 제조방법
CN105326864A (zh) * 2015-11-30 2016-02-17 奥思达干细胞有限公司 一种治疗系统性红斑狼疮的干细胞制剂及其制备方法
WO2017100498A1 (en) 2015-12-11 2017-06-15 The Johns Hopkins University Isolation of fusion-competent myoblasts and therapeutic applications thereof related to muscular dystrophy
CN105754936B (zh) * 2016-02-25 2018-06-08 付清玲 人诱导性多能干细胞诱导为间充质干细胞的方法
JP7048977B2 (ja) * 2016-03-16 2022-04-06 サイナータ セラピューティクス リミテッド コロニー形成培地及びその使用
CN105769911A (zh) * 2016-03-23 2016-07-20 中国人民解放军第二军医大学 间充质干细胞诱导斑秃处毛发再生的方法及应用
US20200140851A1 (en) * 2016-08-23 2020-05-07 The Scripps Research Institute Methods and Compositions Related to In Vivo Selection of Functional Molecules
KR101971323B1 (ko) * 2016-10-17 2019-04-23 사회복지법인 삼성생명공익재단 면역질환 치료를 위한 고효능 줄기세포 선별방법
KR101971322B1 (ko) * 2016-10-17 2019-04-23 사회복지법인 삼성생명공익재단 Ｓｏｃｓ의　발현　또는　활성　억제를　이용한　고효능 줄기세포 선별방법
CN108121161A (zh) * 2016-11-26 2018-06-05 中国科学院大连化学物理研究所 一种高通量形成拟胚体的微阵列芯片的制备方法与应用
EP3559026A4 (en) * 2016-12-23 2020-07-01 Stembios Technologies, Inc. USE OF SOMATIC STEM CELLS TO DECREASE IL-6 LEVEL
CN106754715A (zh) * 2017-02-13 2017-05-31 四川新生命干细胞科技股份有限公司 一种用于造血干细胞培养的滋养层的制备方法
US20200085876A1 (en) * 2017-03-17 2020-03-19 Senti Biosciences, Inc. Immunomodulating cell circuits
KR20180112547A (ko) * 2017-04-04 2018-10-12 경북대학교 산학협력단 역분화 줄기세포의 지속적인 계대배양을 통한 중간엽 줄기세포로의 분화방법
AU2018251898A1 (en) 2017-04-13 2019-10-31 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
KR20230035710A (ko) 2017-05-26 2023-03-14 스테미넌트 바이오테라퓨틱스 인크. 폴리글루타민(polyq) 질병에 대한 치료법
KR20210118479A (ko) 2017-05-26 2021-09-30 카이트 파마 인코포레이티드 배아 중간엽 전구 세포를 제조하고 사용하는 방법
EP3653700A4 (en) * 2017-07-13 2021-04-14 National University Corporation Tokyo Medical and Dental University ARTIFICIAL TENDON OR TISSUE MADE WITH THE HELP OF A THREE-DIMENSIONAL MECHANICAL SIGNALING CELL CULTURE SYSTEM
CN107460169B (zh) * 2017-07-14 2020-12-11 中国科学院广州生物医药与健康研究院 维生素c在制备培养基中的用途
CN107326013B (zh) * 2017-07-28 2020-08-07 杨涛 定向诱导hiPSC分化后的神经细胞体系、诱导方法及应用
CN109666630A (zh) * 2017-10-17 2019-04-23 澳门大学 多能干细胞分化为间充质干细胞的方法及其培养基和应用
AU2018364852B2 (en) * 2017-11-10 2022-06-30 Regenesis Science Co., Ltd. Method for producing cultured cell, and method for producing therapeutic agent for spinal cord injury disease
US20210403871A1 (en) * 2017-11-28 2021-12-30 Inno-Health Technology Co., Ltd. Methods of producing populations of mesenchymal stem cells from peripheral blood and uses thereof
CN108324993B (zh) * 2018-01-15 2020-11-03 朱剑虹 一种诱导毛发再生的干细胞复合体、其制备方法及应用
CN108570447A (zh) * 2018-01-26 2018-09-25 皓昇莱生物制药有限公司 一种筛选分化hPSCs向MSCs的方法
CN108570448B (zh) * 2018-01-26 2019-04-02 皓昇莱生物制药有限公司 一种高效的hPSCs向MSCs分化的方法
KR20200141447A (ko) * 2018-03-06 2020-12-18 오리그3엔, 인코포레이티드 Ipsc-유래 세포 조성물, 및 연골 수복을 위한 관련된 시스템 및 방법
CN110295145B (zh) * 2018-03-22 2020-10-16 苏州麦迪耐斯医药科技有限公司 一种体外培养脑肿瘤细胞的培养液及培养方法
CN108504627A (zh) * 2018-04-02 2018-09-07 中国人民解放军陆军军医大学第二附属医院 人类黄韧带干细胞的提取方法
CN108498452A (zh) * 2018-04-10 2018-09-07 上海交通大学医学院附属仁济医院 一种用于治疗勃起功能障碍的含干细胞可注射水凝胶及其制备方法
JP2021532736A (ja) * 2018-06-06 2021-12-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California 神経幹細胞組成物および神経変性障害を処置するための方法
CN109055307B (zh) * 2018-08-26 2021-06-11 杭州爱唯生命科技有限公司 一种bmp-2激活剂及在干细胞诱导分化方面的应用
AU2019359890B2 (en) 2018-10-17 2024-10-24 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
CN110352951A (zh) * 2018-11-15 2019-10-22 崔磊 一种无血清无dmso组织工程骨冻存液及其制备和冻存方法
CN109536444B (zh) * 2018-12-11 2022-06-28 吉林省拓华生物科技有限公司 一种适用于恶性实体瘤肿瘤浸润t淋巴细胞的分离诱导方法
WO2020131582A1 (en) * 2018-12-17 2020-06-25 President And Fellows Of Harvard College Bioengineered scaffolds for modulation of immune system and the uses thereof
AU2020228979B2 (en) * 2019-02-27 2025-05-29 Takeda Pharmaceutical Company Limited Improved stem cell populations for allogeneic therapy
WO2020181130A2 (en) * 2019-03-05 2020-09-10 MiRagen Therapeutics, Inc. Polynucleotide conjugates and uses thereof
US11878037B2 (en) 2019-05-31 2024-01-23 Figene, Llc Concurrent activation of regenerative and tolerogenic processes by fibroblast-based compositions for the treatment of multiple sclerosis
EP3983528A1 (en) * 2019-06-14 2022-04-20 FUJIFILM Cellular Dynamics, Inc. Methods for the production of multiple lineages from induced pluripotent stem cells using charged surfaces
CN112094804B (zh) * 2019-06-18 2024-05-14 中国医学科学院基础医学研究所 一种异质性干细胞群、其制备方法及用途
JP7391181B2 (ja) * 2019-07-26 2023-12-04 プレクソジェン インコーポレイテッド 人工多能性幹細胞（ｉＰＳＣ）由来間葉系幹細胞の前駆細胞、及びその製造方法
CN110499282B (zh) * 2019-09-03 2021-05-11 广州赛莱拉干细胞科技股份有限公司 一种培养基及其应用和诱导肌腱干细胞向脂肪细胞分化的方法
CN110713973B (zh) * 2019-09-30 2021-05-14 浙江大学 一种诱导多能干细胞分化为间充质干细胞的培养基组合及方法
CN110862983B (zh) * 2019-11-05 2021-04-06 桂林医学院 一种特异靶向小鼠Gdf5基因的sgRNA导向序列及其应用
WO2021104453A1 (en) * 2019-11-28 2021-06-03 The University Of Hong Kong Mesenchymal stromal cells as a reprogramming source for ipsc induction
CN113018316A (zh) * 2019-12-24 2021-06-25 厦门大学 多能干细胞来源的间充质干细胞在修复皮肤损伤中的应用
CN111454892A (zh) * 2020-03-12 2020-07-28 成都世联康健生物科技有限公司 牙间充质干细胞培养基及在牙髓干细胞内的活性验证方法
CN111471648A (zh) * 2020-04-10 2020-07-31 南京大学 一种预处理活化的间充质干细胞的制备方法及其在髓系白血病治疗中的应用
TW202208613A (zh) * 2020-05-05 2022-03-01 美商加速生物科學有限公司 非永生的多潛能幹細胞
US20230242873A1 (en) * 2020-05-13 2023-08-03 Figene, Llc Fibroblast based therapy for treatment of parkinson's disease
US20210355444A1 (en) * 2020-05-13 2021-11-18 Ever Supreme Bio Technology Co., Ltd Method for producing erythroid cells and/or erythrocytes
CN111557952A (zh) * 2020-05-28 2020-08-21 澳门大学 间充质干细胞在制备用于促进脂肪移植的制剂中的应用
WO2022016166A2 (en) * 2020-06-02 2022-01-20 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Differentiation of trophectoderm lineage cells from pluripotent stem cells
WO2021262619A1 (en) * 2020-06-24 2021-12-30 Zhen Ma Generation of perinatal-like mesenchymal stem cells from human induced pluripotent stem cells
WO2022004938A1 (ko) * 2020-06-30 2022-01-06 주식회사 미래셀바이오 유사 중간엽 줄기세포의 제조방법
CN112359012B (zh) * 2020-10-22 2022-11-25 中国科学院水生生物研究所 诱导多能干细胞分化制备心脏瓣膜内皮细胞的方法及其应用
CN114504596A (zh) * 2020-10-23 2022-05-17 厦门大学 多能干细胞来源的间充质干细胞在治疗银屑病中的应用
CN113462642A (zh) * 2021-08-12 2021-10-01 呈诺再生医学科技(珠海横琴新区)有限公司 间充质干细胞的快速诱导分化方法、试剂盒及其应用
WO2023090589A1 (ko) * 2021-11-22 2023-05-25 주식회사 미래셀바이오 전분화능 줄기세포 기반 과민성 면역반응에 의한 피부질환의 예방 또는 치료용 조성물
CN113975298A (zh) * 2021-11-29 2022-01-28 海南康盾生物制药有限公司 一种用于小儿自闭症的细胞治疗药物及其制备方法
CN114438037B (zh) * 2022-01-25 2024-06-04 深圳市乐土生物医药有限公司 一种制备诱导性间充质干细胞的方法
CN114574436A (zh) * 2022-05-06 2022-06-03 深圳汉盛汇融再生医学科技有限公司 一种治疗膝关节退行性病变的干细胞制剂及其制备方法
CN115785221B (zh) * 2022-07-11 2023-07-04 北京大学 一种转录因子hoxb9磷酸化位点的特异性抗体及其制备方法和应用
AU2024247977A1 (en) * 2023-03-31 2025-11-13 Pluristyx, Inc. Conditionally immortalized stem cells and uses thereof
CN116376828B (zh) * 2023-06-02 2023-08-11 成都云测医学生物技术有限公司 一种诱导CD4+T细胞生成Treg细胞的方法及应用
WO2025221594A1 (en) * 2024-04-16 2025-10-23 The Regents Of The University Of California Methods for generating dopaminergic neurons and organoids thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5981180A (en) 1995-10-11 1999-11-09 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and methods
JP4357112B2 (ja) 1997-10-14 2009-11-04 ルミネックス コーポレイション 精密蛍光染色された粒子及びその製造及び使用方法
ATE239801T1 (de) 1998-01-22 2003-05-15 Luminex Corp Mikropartikel mit multiplen fluoreszenz-signalen
JP4526186B2 (ja) 1998-06-08 2010-08-18 オシリス セラピューティクス，インコーポレイテッド 造血幹細胞を試験管内で維持する方法と組成物
KR100696407B1 (ko) 1999-04-16 2007-03-19 더블유엠. 마쉬 라이스 유니버시티 폴리(프로필렌 푸마레이트)-디아크릴레이트 마크로머와가교결합된 생분해성 폴리(프로필렌 푸마레이트) 네트워크
US6355699B1 (en) 1999-06-30 2002-03-12 Ethicon, Inc. Process for manufacturing biomedical foams
CA2478987C (en) 2002-03-15 2014-02-11 Wicell Research Institute, Inc. Method for generating primate trophoblasts
US7642091B2 (en) * 2005-02-24 2010-01-05 Jau-Nan Lee Human trophoblast stem cells and use thereof
US20080199849A1 (en) 2005-09-02 2008-08-21 Agency For Science, Technology And Research Method of Deriving Progenitor Cell Line
US20090304647A1 (en) * 2008-05-30 2009-12-10 The Board Of Trustees Of The University Of Illinois Production of Neural Stem Cells from Bone Marrow Tissue and Use Thereof
JP2010094062A (ja) 2008-10-15 2010-04-30 Saitama Medical Univ 間葉系幹細胞の多分化能維持用培地、培養方法、及び分化方法
WO2010077955A1 (en) * 2008-12-17 2010-07-08 The Scripps Research Institute Generation and maintenance of stem cells
US20110088107A1 (en) * 2009-04-24 2011-04-14 Yaqub Hanna Compositions and methods for deriving or culturing pluripotent cells
KR101755214B1 (ko) * 2009-08-12 2017-07-07 고쿠리츠 다이가쿠 호진 교토 다이가쿠 만능줄기세포의 신경전구세포로의 분화 유도 방법
KR101193541B1 (ko) 2009-08-24 2012-10-22 한국과학기술원 인간 배아줄기세포에서 중간엽 줄기세포로 분화시키는 방법
CA2818234C (en) 2010-11-15 2023-03-07 Jau-Nan Lee Generation of neural stem cells from human trophoblast stem cells
TWI812867B (zh) 2011-11-30 2023-08-21 安斯泰來再生醫藥協會 利用血管母細胞產生間葉基質細胞之方法
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto

Also Published As

Publication number Publication date
AU2013290146A1 (en) 2015-02-05
US9725698B2 (en) 2017-08-08
CN104487568B (zh) 2017-08-15
EP2872619A4 (en) 2016-03-02
WO2014011881A3 (en) 2014-04-03
HK1208055A1 (en) 2016-02-19
CN104487568A (zh) 2015-04-01
EP2872619B1 (en) 2018-02-14
US20190167733A1 (en) 2019-06-06
US20150191699A1 (en) 2015-07-09
WO2014011881A2 (en) 2014-01-16
CA2876512A1 (en) 2014-01-16
EP2872619A2 (en) 2015-05-20
US10842826B2 (en) 2020-11-24
CA3176706A1 (en) 2014-01-16
JP2015523083A (ja) 2015-08-13
CA2876512C (en) 2022-12-13
US20210085725A1 (en) 2021-03-25
US20170290864A1 (en) 2017-10-12
AU2013290146B2 (en) 2018-01-18
US10226488B2 (en) 2019-03-12

Similar Documents

Publication Publication Date Title
JP6277187B2 (ja) ヒト胚性幹細胞由来の間葉系様幹細胞、方法およびその使用
US12209255B2 (en) Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
US10722541B2 (en) Methods for treating radiation or chemical injury
ES2927175T3 (es) Método de producción de micropartículas
JP2019535691A (ja) 間葉系幹細胞集団、それらの生成物およびそれらの使用
Kerrigan et al. Stem cell therapy of gliomas
ITUB20159750A1 (it) Metodo per la promozione ed il miglioramento delle proprieta? del tessuto adiposo, tessuto e cellule ottenute tramite detto metodo
AU2023310144A1 (en) Methods of treating brain injury
HK1208055B (en) Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
HK1136846A1 (en) Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
HK1136846B (en) Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160708

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170817

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171226

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180115

R150 Certificate of patent or registration of utility model

Ref document number: 6277187

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250